COMPANY PROFILE / #2055
Imagene
Miami, FLVenture Capital-Backed
OVERVIEW
Developer of AI-based oncology diagnostics software designed for accelerating biomarker detection and supporting precision cancer treatment. The company's software applies deep learning algorithms to analyze biopsy tissue images, identify clinically relevant biomarkers, and support translational research and drug development, enabling healthcare providers and researchers to reduce diagnostic turnaround times and enhance treatment personalization.
已融资44.20
最新估值80.49
员工数40
成立年份2020
公司概况
- Companies
- Imagene
- Description
- Developer of AI-based oncology diagnostics software designed for accelerating biomarker detection and supporting precision cancer treatment. The company's software applies deep learning algorithms to analyze biopsy tissue images, identify clinically relevant biomarkers, and support translational research and drug development, enabling healthcare providers and researchers to reduce diagnostic turnaround times and enhance treatment personalization.
- Website
- imagene-ai.com
- HQ Location
- Miami, FL
- Year Founded
- 2020
- Keywords
- ai testing, biomarker detection, cancer diagnostics, cancer research, cancer testing, cancer treatment, digital healthcare, genomics testing, image analysis system, molecular testing, precision oncology, precision treatment
- Competitors
- Nucleai, PreciseDx, Strata Oncology, GenomOncology, Ibex Medical Analytics, RADLogics, CureMetrix, Paige, Advantis Medical Imaging, Dascena, Deep Lens, PredxBio, Inspirata, Pie Medical Imaging, Aidoc, MedyMatch Technology, VoxelCloud, C2i Genomics, KEW, Quantib, Zebra Medical Vision, SigTuple, Arterys, Biotheranostics, PathAI, Epic Sciences, Circle Cardiovascular Imaging, Notable Labs, Mirada Medical, Riverain Technologies, Biocept, Keen Eye, ImageIQ, Proscia, Lifetrack Medical Systems, Adaptive Biotechnologies, TomTec Imaging Systems, Harrison-AI, Tempus AI, Menarini Silicon Biosystems, GRAIL, Intrinsic Imaging, Guardant Health, Medical Metrics
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 44.20
- First Financing Date
- —
- First Financing Size
- —
- First Financing Valuation
- —
- Last Financing Date
- 01-Jul-2025
- Last Financing Deal Type
- Later Stage VC
- Last Financing Size
- 22.70
- Last Financing Valuation
- 80.49
- Last Financing Status
- Completed
- Last Known Valuation
- 80.49
- Last Known Valuation Date
- 01-Jul-2025
- Last Known Valuation Deal Type
- Later Stage VC
- Valuation Estimate
- 138.35
- Valuation Estimate Growth Rate
- 71.88%
- Active Investors
- Aguras Pathology Investments, ARC Innovation Center, Blumberg Capital, David Agus, Eyal Gura, Katao Venture Partners, Lawrence Ellison
- # Active Investors
- 7
- Acquirers
- —
团队与联系人
- Employees
- 40
- Employee Growth %
- 25.00%
- Employee History
- 2026: 40, 2025: 32, 2024: 30, 2023: 31, 2022: 31, 2021: 14
- Primary Contact
- Dean Bitan
- Primary Contact Title
- Co-Founder, Chief Executive Officer & Board Member
- Primary Contact Email
- dean@imagene-ai.com
- Primary Contact Phone
- —
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- 0.65%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 96
- Size Multiple
- 5.00x
- Size Multiple % Change
- 0.00%
- Size Multiple Change
- 0.00x
- Size Multiple Percentile
- 80
- Majestic Referring Domains
- —
- SimilarWeb Unique Visitors
- 406
- SimilarWeb Unique Visitors Change
- 19
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 5%
- Success Probability Over Time – 3 Year
- 16%
- Success Probability Over Time – 5 Year
- 27%
记录来源：public.companies · 原始序号 #2055 · 所有字段均按数据库原值展示。